ARDX

Ardelyx, Inc. NASDAQ

Healthcare ·Biotechnology ·US · ardelyx.com

$7.30

Mkt Cap $1.8B

52w Low $3.21 78.8% of range 52w High $8.40

50d MA $6.04 200d MA $5.97

P/E (TTM) -26.5x

EV/EBITDA -53.1x

P/B 9.9x

Debt/Equity 1.3x

ROE -36.9%

P/FCF -32.0x

RSI (14) —

ATR (14) —

Beta 0.66

50d MA $6.04

200d MA $5.97

Avg Volume 3.6M

About

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clini…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Apr 30, 2026	AMC	-0.13	-0.15	-15.4%	6.33	-5.2%	+8.7%	—	—	—	—	—	—
Feb 19, 2026	AMC	0.02	0.02	+0.0%	6.74	-3.7%	-15.0%	-14.7%	-2.7%	-2.7%	-1.6%	-21.2%	—
Oct 30, 2025	AMC	-0.06	-0.00	+93.3%	5.01	+28.3%	+21.0%	+18.2%	+11.8%	+18.8%	+12.8%	+11.6%	—
Aug 4, 2025	AMC	-0.13	-0.08	+38.5%	4.39	+15.7%	+16.9%	+18.5%	+17.1%	+18.7%	+23.0%	+48.3%	—
May 1, 2025	AMC	-0.10	-0.17	-70.0%	5.47	-26.0%	-24.5%	-31.6%	-27.8%	-32.4%	-33.5%	-29.6%	—
Feb 20, 2025	AMC	0.02	0.02	+0.0%	5.72	+0.2%	-11.5%	-10.3%	-9.4%	-10.8%	-8.7%	-8.2%	—
Oct 31, 2024	AMC	-0.05	-0.00	+93.2%	5.87	+2.0%	+3.7%	+0.3%	-2.6%	+10.6%	+8.7%	-5.6%	—
Aug 1, 2024	AMC	-0.10	-0.07	+30.0%	5.50	+2.7%	+10.0%	+6.0%	+10.5%	+0.9%	+6.7%	+2.4%	—
May 2, 2024	AMC	-0.13	-0.11	+15.4%	6.79	+23.1%	+28.4%	+34.8%	+37.1%	+24.9%	+18.7%	+1.9%	—
Feb 22, 2024	AMC	-0.09	-0.12	-33.3%	8.82	-7.5%	-1.6%	+5.3%	+9.6%	+7.3%	+5.7%	-12.7%	—
Oct 31, 2023	AMC	-0.11	0.03	+127.3%	3.95	+0.0%	-0.3%	+1.5%	+1.8%	+1.3%	+3.0%	+14.2%	—
Aug 2, 2023	AMC	-0.12	-0.08	+33.3%	4.04	+0.0%	-1.0%	-3.2%	-7.2%	-4.0%	-2.0%	+19.3%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Feb 23	Wedbush	Maintains	Outperform → Outperform	—	$5.73	$5.66	-1.2%	+0.3%	+14.5%	+14.5%	+15.7%	+14.3%
Feb 20	BTIG	Maintains	Buy → Buy	—	$6.74	$6.49	-3.7%	-15.0%	-14.7%	-2.7%	-2.7%	-1.6%
Feb 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.74	$6.49	-3.7%	-15.0%	-14.7%	-2.7%	-2.7%	-1.6%
Jan 29	BTIG	Maintains	Buy → Buy	—	$7.86	$7.89	+0.4%	-0.1%	-2.2%	-0.9%	-1.5%	-6.1%
Jan 21	Wedbush	Maintains	Outperform → Outperform	—	$7.76	$7.79	+0.4%	+3.0%	+2.2%	+0.1%	+0.5%	+1.7%
Jan 9	BTIG	Maintains	Buy → Buy	—	$7.00	$7.30	+4.3%	+10.6%	+5.1%	+0.6%	-1.6%	+0.6%
Jan 9	Piper Sandler	Upgrade	Neutral → Overweight	—	$7.00	$7.30	+4.3%	+10.6%	+5.1%	+0.6%	-1.6%	+0.6%
Jan 9	Citigroup	Maintains	Buy → Buy	—	$7.00	$7.30	+4.3%	+10.6%	+5.1%	+0.6%	-1.6%	+0.6%
Nov 4	Piper Sandler	Maintains	Neutral → Neutral	—	$5.92	$5.84	-1.4%	-5.4%	+0.5%	-4.6%	-5.6%	-4.6%
Nov 3	Citigroup	Maintains	Buy → Buy	—	$6.06	$6.07	+0.2%	-2.3%	-7.6%	-1.8%	-6.8%	-7.8%
Oct 31	TD Cowen	Maintains	Buy → Buy	—	$5.01	$6.43	+28.3%	+21.0%	+18.2%	+11.8%	+18.8%	+12.8%
Aug 6	Piper Sandler	Maintains	Neutral → Neutral	—	$5.13	$5.13	+0.0%	+1.4%	+0.2%	+1.6%	+5.3%	+9.2%
Aug 5	Raymond James	Maintains	Outperform → Outperform	—	$4.39	$5.08	+15.7%	+16.9%	+18.5%	+17.1%	+18.7%	+23.0%
Aug 5	Wedbush	Maintains	Outperform → Outperform	—	$4.39	$5.08	+15.7%	+16.9%	+18.5%	+17.1%	+18.7%	+23.0%
May 2	Citigroup	Maintains	Buy → Buy	—	$5.47	$4.05	-26.0%	-24.5%	-31.6%	-27.8%	-32.4%	-33.5%
Feb 21	Raymond James	Maintains	Strong Buy → Strong Buy	—	$5.72	$5.73	+0.2%	-11.5%	-10.3%	-9.4%	-10.8%	-8.7%
Feb 21	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$5.72	$5.73	+0.2%	-11.5%	-10.3%	-9.4%	-10.8%	-8.7%
Jan 27	Piper Sandler	Maintains	Neutral → Neutral	—	$5.52	$5.52	+0.0%	-0.9%	-0.5%	-0.7%	-2.9%	-2.9%
Jan 16	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$5.35	$5.33	-0.4%	-3.6%	-6.4%	-8.2%	-5.6%	+3.0%
Jan 2	Jefferies	Maintains	Buy → Buy	—	$5.07	$5.03	-0.8%	+1.0%	-2.0%	-1.4%	+6.7%	+5.3%
Nov 11	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$5.07	$4.89	-3.6%	-3.6%	-9.5%	-11.2%	-7.1%	-2.0%
Nov 4	Citigroup	Maintains	Buy → Buy	—	$6.09	$5.96	-2.1%	-3.3%	-6.1%	+6.6%	+4.8%	-16.7%
Nov 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.87	$5.99	+2.0%	+3.7%	+0.3%	-2.6%	+10.6%	+8.7%
Aug 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.05	$5.45	-9.9%	-3.6%	+0.5%	-8.3%	-3.0%	-5.8%
Aug 2	Wedbush	Maintains	Outperform → Outperform	—	$5.50	$5.65	+2.7%	+10.0%	+6.0%	+10.5%	+0.9%	+6.7%
Aug 2	Citigroup	Maintains	Buy → Buy	—	$5.50	$5.65	+2.7%	+10.0%	+6.0%	+10.5%	+0.9%	+6.7%
Jul 18	Wedbush	Maintains	Outperform → Outperform	—	$5.75	$5.80	+0.9%	-4.5%	-4.2%	-0.9%	-1.0%	-2.3%
Jul 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.75	$5.80	+0.9%	-4.5%	-4.2%	-0.9%	-1.0%	-2.3%
Jul 3	Citigroup	Maintains	Buy → Buy	—	$5.28	$5.53	+4.7%	+0.8%	+0.2%	+3.2%	+5.3%	+5.3%
May 24	Piper Sandler	Maintains	Overweight → Overweight	—	$7.44	$7.33	-1.5%	-9.3%	-7.3%	-11.2%	-8.9%	-7.8%
May 24	Wedbush	Maintains	Outperform → Outperform	—	$7.44	$7.33	-1.5%	-9.3%	-7.3%	-11.2%	-8.9%	-7.8%
May 3	Citigroup	Maintains	Buy → Buy	—	$6.79	$8.36	+23.1%	+28.4%	+34.8%	+37.1%	+24.9%	+18.7%
May 3	Wedbush	Maintains	Outperform → Outperform	—	$6.79	$8.36	+23.1%	+28.4%	+34.8%	+37.1%	+24.9%	+18.7%
Apr 17	Wedbush	Maintains	Outperform → Outperform	—	$6.71	$6.83	+1.8%	-2.4%	-4.0%	-3.4%	-3.0%	-4.8%
Feb 23	Piper Sandler	Maintains	Overweight → Overweight	—	$8.82	$8.16	-7.5%	-1.6%	+5.3%	+9.6%	+7.3%	+5.7%
Feb 23	Wedbush	Maintains	Outperform → Outperform	—	$8.82	$8.16	-7.5%	-1.6%	+5.3%	+9.6%	+7.3%	+5.7%
Jan 12	Wedbush	Maintains	Outperform → Outperform	—	$8.72	$8.81	+1.0%	+3.6%	+0.7%	-2.3%	-7.8%	-5.0%
Jan 10	Citigroup	Maintains	Buy → Buy	—	$9.10	$9.18	+0.9%	-0.2%	-4.2%	-0.8%	-3.5%	-6.4%
Jan 9	Raymond James	Maintains	Strong Buy → Strong Buy	—	$8.18	$8.17	-0.1%	+11.2%	+11.0%	+6.6%	+10.4%	+7.3%
Dec 1	Wedbush	Maintains	Outperform → Outperform	—	$4.51	$4.50	-0.2%	+5.5%	+10.0%	+11.3%	+14.0%	+17.5%
Nov 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.95	$3.95	+0.0%	-0.3%	+1.5%	+1.8%	+1.3%	+3.0%
Sep 13	Wedbush	Maintains	Outperform → Outperform	—	$4.83	$4.86	+0.6%	-5.0%	-3.5%	-5.8%	-13.7%	-17.0%
Sep 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.73	$4.77	+0.8%	+2.1%	-3.0%	-1.5%	-3.8%	-11.8%
Aug 25	Cantor Fitzgerald	Upgrade	Neutral → Overweight	—	$3.51	$3.69	+5.1%	+12.3%	+21.1%	+19.7%	+20.8%	+21.4%
Aug 3	Ladenburg Thalmann	Maintains	Buy → Buy	—	$4.04	$4.04	+0.0%	-1.0%	-3.2%	-7.2%	-4.0%	-2.0%
Apr 17	Wedbush	Maintains	Outperform → Outperform	—	$4.71	$4.67	-0.8%	+4.5%	+3.8%	+4.0%	+1.5%	+5.1%
Mar 3	Wedbush	Upgrade	Neutral → Outperform	—	$2.89	$3.40	+17.6%	+32.2%	+34.9%	+36.3%	+40.8%	+32.2%
Dec 30	Citigroup	Maintains	Buy → Buy	—	$2.53	$2.59	+2.4%	+12.6%	+5.9%	+11.1%	+8.7%	+13.4%
Nov 17	Piper Sandler	Upgrade	Neutral → Overweight	—	$1.22	$1.97	+61.5%	+41.0%	+70.5%	+69.7%	+51.6%	+45.1%
May 19	Piper Sandler	Maintains	Neutral → Neutral	—	$0.66	$0.68	+2.6%	+2.6%	-0.8%	-4.3%	-9.6%	-8.1%

Recent Filings

8-K · 7.01 ! Medium

Ardelyx, Inc. -- 8-K 7.01: Regulation FD Disclosure

Ardelyx will host a February 19, 2026 conference call to discuss fourth-quarter and full-year 2025 financial results, with an earnings presentation available for investor review.

Feb 19

Data updated apr 24, 2026 6:48pm · Source: massive.com